Literature DB >> 17555462

National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing.

Azra Mahmud1, Kathleen Bennett, Ifeanyi Okechukwu, John Feely.   

Abstract

AIMS: To examine if appropriate antithrombotic therapy in atrial fibrillation is implemented nationally.
METHODS: Using prescriptions for digoxin as a surrogate for atrial fibrillation, we identified its coprescription with antithrombotic therapy, aspirin or warfarin in a national prescribing database in 27 571 patients over 45 years old.
RESULTS: Proportionately significantly more men were on warfarin, and use in those >75 years old was three times less than in those <65 years. Reluctance to use antithrombotics was confirmed in a postal survey.
CONCLUSION: Data suggest a missed opportunity to prevent stroke with women and those >75 years old least likely to receive warfarin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555462      PMCID: PMC2203268          DOI: 10.1111/j.1365-2125.2007.02954.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse
Journal:  Eur Heart J       Date:  2001-10       Impact factor: 29.983

2.  Identification of patients with atrial fibrillation in general practice: a study of screening methods.

Authors:  M Sudlow; H Rodgers; R A Kenny; R Thomson
Journal:  BMJ       Date:  1998-08-01

3.  Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; Alessandro Capucci; Gregory Y H Lip; S Bertil Olsson; Martin H Prins; Fred H Nieman; José López-Sendón; Panos E Vardas; Etienne Aliot; Massimo Santini; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2006-05-26       Impact factor: 29.983

4.  Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.

Authors:  R G Hart; O Benavente; R McBride; L A Pearce
Journal:  Ann Intern Med       Date:  1999-10-05       Impact factor: 25.391

5.  Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.

Authors:  Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

7.  Community-based study of atrial fibrillation and stroke prevention.

Authors:  S White; J Feely; D O'Neill
Journal:  Ir Med J       Date:  2004-01

8.  Implementation of anticoagulation guidelines in general practice: a practice report.

Authors:  C T O Dubhghaill; L Moonen; A O'Loughlin; S O'Keeffe; D Egan; A W Murphy
Journal:  Ir Med J       Date:  2003 Nov-Dec

9.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Authors:  P A Wolf; R D Abbott; W B Kannel
Journal:  Stroke       Date:  1991-08       Impact factor: 7.914

10.  Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care.

Authors:  David Williams; Kathleen Bennett; John Feely
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

View more
  7 in total

1.  Stroke prevention in atrial fibrillation--things can only get better.

Authors:  Gregory Y H Lip; Timothy Watson
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

2.  The gap between indicated and prescribed stroke prevention therapies in a high-risk geriatric population.

Authors:  Mohammed Shurrab; Eugene Crystal; Denis O'Donnell; Hrishikesh Navare; Paula Neves; Rasha Khatib; Ilan Lashevsky; David Newman
Journal:  J Interv Card Electrophysiol       Date:  2017-01-16       Impact factor: 1.900

Review 3.  Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.

Authors:  Christopher J Boos; Michael Nam; A J Camm
Journal:  Heart Fail Rev       Date:  2013-06-25       Impact factor: 4.214

4.  A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers.

Authors:  Renli Teng; Kathleen Butler
Journal:  Eur J Clin Pharmacol       Date:  2013-06-09       Impact factor: 2.953

5.  Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now.

Authors:  Beata V Bajorek; Shu Ren
Journal:  Int J Clin Pharm       Date:  2011-12-17

6.  Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

Authors:  A John Camm; Gabriele Accetta; Giuseppe Ambrosio; Dan Atar; Jean-Pierre Bassand; Eivind Berge; Frank Cools; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Gloria Kayani; Yukihiro Koretsune; Lorenzo G Mantovani; Frank Misselwitz; Seil Oh; Alexander G G Turpie; Freek W A Verheugt; Ajay K Kakkar
Journal:  Heart       Date:  2016-09-19       Impact factor: 5.994

Review 7.  Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?

Authors:  Gregory Y H Lip; Sana M Al-Khatib; Francisco G Cosio; Amitava Banerjee; Irina Savelieva; Jeremy Ruskin; Dan Blendea; Stanley Nattel; Joseph De Bono; Jennifer M Conroy; Paul L Hess; Eduard Guasch; Jonathan L Halperin; Paulus Kirchhof; M Dolores G Cosio; A John Camm
Journal:  J Am Heart Assoc       Date:  2014-08-27       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.